key: cord-0865111-dpjhuy8u authors: Gillis, Avi; Ben Yaacov, Anat; Agur, Zvia title: A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker date: 2021-03-01 journal: Front Immunol DOI: 10.3389/fimmu.2021.616881 sha: 09f06a1482730b859a28e613503c7ad9426a51f4 doc_id: 865111 cord_uid: dpjhuy8u Background: Recently, there has been a growing interest in applying immune checkpoint blockers (ICBs), so far used to treat cancer, to patients with bacterial sepsis. We aimed to develop a method for predicting the personal benefit of potential treatments for sepsis, and to apply it to therapy by meropenem, an antibiotic drug, and nivolumab, a programmed cell death-1 (PD-1) pathway inhibitor. Methods: We defined an optimization problem as a concise framework of treatment aims and formulated a fitness function for grading sepsis treatments according to their success in accomplishing the pre-defined aims. We developed a mathematical model for the interactions between the pathogen, the cellular immune system and the drugs, whose simulations under diverse combined meropenem and nivolumab schedules, and calculation of the fitness function for each schedule served to plot the fitness landscapes for each set of treatments and personal patient parameters. Results: Results show that treatment by meropenem and nivolumab has maximum benefit if the interval between the onset of the two drugs does not exceed a dose-dependent threshold, beyond which the benefit drops sharply. However, a second nivolumab application, within 7–10 days after the first, can extinguish a pathogen which the first nivolumab application failed to remove. The utility of increasing nivolumab total dose above 6 mg/kg is contingent on the patient's personal immune attributes, notably, the reinvigoration rate of exhausted CTLs and the overall suppression rates of functional CTLs. A baseline pathogen load, higher than 5,000 CFU/μL, precludes successful nivolumab and meropenem combination therapy, whereas when the initial load is lower than 3,000 CFU/μL, meropenem monotherapy suffices for removing the pathogen. Discussion: Our study shows that early administration of nivolumab, 6 mg/kg, in combination with antibiotics, can alleviate bacterial sepsis in cases where antibiotics alone are insufficient and the initial pathogen load is not too high. The study pinpoints the role of precision medicine in sepsis, suggesting that personalized therapy by ICBs can improve pathogen elimination and dampen immunosuppression. Our results highlight the importance in using reliable markers for classifying patients according to their predicted response and provides a valuable tool in personalizing the drug regimens for patients with sepsis. Bacterial sepsis is a severe life-threatening systemic dysregulated pro-and anti-inflammatory response to infection, often resulting in tissue damage, multiple organ dysfunction, and ultimately death (1) . Recent global estimates of bacterial sepsis epidemiology report 48·9 million cases of sepsis and 11 million sepsis-related deaths in 2017, representing 19·7% of all deaths worldwide. Despite the global trend of decreasing sepsis burden, progress in the treatment of sepsis has been modest (2) (3) (4) . An immediate administration of broad-spectrum antibiotics is the first-line treatment for the improvement of patient outcomes and reduction of mortality and morbidity due to sepsis (5) (6) (7) (8) . Efforts were also made to avoid hyper-inflammation, which characterizes the early stage of this disorder, by administering anti-inflammatory agents, including toll-like receptor (TLR) antagonists, anti-cytokine therapies, and corticosteroids (3) . Disappointingly, these have often failed in relieving the septic condition (9) . Patients who endure the initial phase of hyper-inflammation frequently enter a second, lengthier phase of immunosuppression, characterized by immune cell depletion and changes in receptor expression patterns, usually resulting in the acquisition of nosocomial infections, and often death (10, 11) . There is an urgent need, therefore, to improve sepsis therapy by minimizing the duration of the immunosuppressive state, or preventing it altogether. In cancer, cytotoxic T lymphocytes (CTLs) expand extensively upon encountering foreign antigens (12) . Following antigen clearance and the resolution of the inflammation, the programmed cell death protein 1 (PD-1) receptors on the surface of CTLs bind to their ligands, PD-L1 and PD-L2, to generate a co-inhibitory signal, which suppresses the CTL expansion (13) . Cancer cells hijack this natural self-constraining mechanism. By expressing the same co-inhibitory signal, they stimulate CTLs to undergo exhaustion, weakening the immune response prematurely and hampering cancer cell clearance (12, 14) . The recently developed immune checkpoint blockers (ICBs) can counteract this cancer-induced ligandreceptor association, enabling reinvigoration of exhausted CTLs, restoration of anticancer immunity and suppression of cancer growth (15) . As PD-1 and PD-L1 are upregulated in septic patients, it is plausible that ICBs, which were developed as oncology drugs, can also be suitable for the treatment of sepsis, preventing the critical immunosuppression phase and overcoming its often-lethal consequences (16, 17) . Several ICBs, studied in murine models of sepsis, show significant effects on restoration of T cell function, reduction of inflammation, and improvement of survival (18) . Recent clinical studies of the PD-1 inhibitor antibody, nivolumab (opdivo R ), first approved for the treatment of melanoma, demonstrated favorable safety and tolerability in the treatment of septic patients (19, 20) . However, excessive inflammation and a constellation of toxicities could still emerge under this immunotherapy (21) (22) (23) (24) (25) , which is one reason successful clinical trials for ICBs in sepsis are still scarce. Possible adverse events include hepatitis, pneumonitis, enterocolitis and grade 3 anemia (26) (27) (28) . Judicious use of ICB therapy, and careful regimen planning, based on assessment of personal benefits and risks for the selected agent(s), is therefore of utmost necessity. Mathematical modeling can help disentangle the dynamic interactions between the pervading pathogen, the host cellular immunity and the drug. To construct a mathematical model, one makes simple assumptions about the major forces in the system, and formalizes them by the succinct language of mathematics. This enables in silico simulations of the system's behavior under different administration schedules of the drug(s), hence predicting the patient response to each application regimen. Models of this kind have proven useful for this purpose in a wide range of medical fields, including cancer immunotherapy by ICBs (29, 30) . In sepsis, previous mathematical modeling has focused mainly on the shift of equilibrium between the pro-and anti-inflammatory signaling cascades, not considering the immunosuppressive arm (31, 32) . Therefore, it was necessary to develop a model of sepsis-associated inflammation that would include potential drivers and inhibitors of immunosuppression. To achieve this goal, Gillis et al. (33) devised "skeletal" mathematical models for bacterial sepsis, formalizing putative mechanisms which govern sepsis-associated inflammation and immunosuppression. Model simulations show that when no pathogen-induced CTL exhaustion is assumed, the immune system can permanently eliminate mild pathogens, while moderate and aggressive pathogens recover concurrently with the cellular immune arm, and by that stimulate another wave of immune reaction. In contrast, simulations of a model that includes the effect of exhaustion show progressively decreasing CTL counts and chronic bacteremia. In the latter scenario, administration of an ICB in combination with antibiotics can lead to pathogen clearance, if the ICB is applied sufficiently early (33) . For proceeding toward the implementation of sepsis immunotherapy in the clinical practice, we aimed to develop an optimization scheme for singling out treatment strategies for bacterial sepsis, which attain maximum efficacy with minimum adverse events. The scheme we developed relied on a general approach for optimizing drug schedules by use of mathematical mechanistic models, developed by Agur et al. (34) . At the core of the method lies a new mathematical mechanistic model, formalizing the dynamic interactions in the drug-host-pathogen system. The new model-an extension of the much simplified models in (33)-was used to evaluate which treatments by the carbapenem antimicrobial agent meropenem, as the representative antibiotics (7) and the PD-1 blocker nivolumab (20) , as the ICB under examination, could optimize bacterial sepsis therapy. We combined the extended disease model with the newly developed pharmacokinetics (PK) and pharmacodynamics (PD) models of the chosen drugs and simulated the combined model within the optimization scheme we had developed. Doing so, we could suggest improved regimens for the drugs used. Due to criticality of the sepsis condition, we chose short-term pathogen elimination (6 weeks) as the primary endpoint in our study (35) . Our disease model, described in Figure 1 , is an extension of the one described in Gillis et al. (33) . In the current embodiment, we took explicit account of the exhaustion process and the reinvigoration of exhausted CTLs. Since sepsis induces a systemic, multi-organ failure, the model's descriptions of the interactions between the pathogen and the immune system of the host, are not limited to a specific organ or tissue, which is to say the model is non-spatial. Rather, the two hematopoietic arms, myeloid and lymphoid, representing the innate and adaptive immune systems, respectively, are taken as the core of these interactions. In our model, hematopoietic stem cells (HSCs) differentiate into each one of the two hematopoietic arms with complementary probabilities, a M for myeloid and 1 − a M ≡ a L for lymphoid. We assumed that the probability of HSCs differentiating into myeloid cells increases with the presence of pathogen, because of the increasing demand for blood neutrophils. This effect is termed emergency granulopoiesis (36) . According to our model, myeloid cells encourage the proliferation of CTLs, while the pathogen depletes them by upregulating the PD-1/PD-L1 pathway, leading to CTL exhaustion, directly reducing their impact (37) . Although the role of antibody-producing B cells in sepsis, serving as gatekeepers of bacterial infection (38) , is more important than previously thought, for the sake of parsimony, B cells and antibodies are neglected in our model, CTLs being the focus of our study in optimizing sepsis therapy. We also allowed for the possibility that the pathogen can indirectly suppress CTLs' proliferation, by exhausting functional CTLs. Exhausted CTLs can hamper the proliferation of functional T cells, e.g., by releasing anti-inflammatory cytokines, such as IL-10 and TGF-β (39), or by suppressing the expression of stimulatory receptors and ligands, such as Human Leukocyte Antigen DR isotype (HLA-DR), by antigen presenting cells (APCs) (40, 41) . In our model, administration of ICBs reinvigorates CTLs that are in the process of exhaustion, returning them to the compartment of functional CTLs (42) . Moreover, the model pathogen grows according to a logistic function, all the while being suppressed by neutrophils and CTLs. The equations representing these processes are given below here (all cells are counted in a volume of 1 µL). (1) f r (N) =q X · N N+N 50 . In Eqs 1-8, M is the number of cells in the myeloid compartment. Neutrophils are by far the most abundant of these (43) , and we therefore evaluated the associated parameters accordingly. For this reason, we refer to the variable M as "neutrophils" when presenting our simulations in the Results section. The variable L is the number of CTLs; L X denotes the number of exhausted CTLs; P is the number of pathogens; f H (P) is the HSC differentiation skew function; f AP (M) is the function expressing the rate of antigen presentation by myeloid cells; f X (P) is the exhaustion rate function; f r (N) is the reinvigoration function; N, nivolumab (ICB) concentration. The parameter N 50 from Eq. 8 is estimated according to Hotchkiss' findings on receptor occupancy, which show a sustained effect of nivolumab for the entire observed period of ∼3 months, even when the drug concentration was significantly reduced. We therefore set this parameter at the relatively low level of 0.3 mg/kg, so that the drug's dose-efficacy function reaches saturation relatively quickly. We deliberately formulated the exhaustion function and the reinvigoration function not to be symmetric. f X (P) is a sigmoid function, such that if P ≪ P γ the exhaustion effect is quite weak (39) . This is to reflect the observation that the onset of exhaustion due to PD-1 binding is a gradual event, induced by a persistently high pathogen load (over 10 3 CFU/µL). In contrast, the pharmacodynamic effect of nivolumab, measured in clinical trials as receptor occupancy, behaves as a hyperbolic function of the dose, hence the formulation of f r (N) (19) . The parameters in Eqs 1-8 are: H, HSC population size; a M , probability of HSC differentiation into a myeloid cell; µ M , neutrophil death rate; r L , CTL proliferation rate; K L , maximum CTL number; µ L , CTL death rate; r P (A), pathogen growth rate, dependent on A, antibiotics concentration; K P , maximum pathogen load; κ M , pathogen killing rate by neutrophils; κ L , pathogen killing rate by CTLs; J P , pathogen load which induces half-maximal pathogen elimination; P α , regulating pathogen load for f H ; α, maximum skew of HSC differentiation into myeloid lineage; β, immunogenicity parameter, representing magnitude of antigen presentation by APCs to CTLs;M, neutrophil number above homeostasis (see below); J M , myeloid number which induces half-maximal antigen presentation by APCs to CTLs; s X , exhausted cell number which induces half of maximal CTL suppression (indirect suppression) 1 ; µ X , maximum CTL exhaustion rate; γ , steepness of exhaustion as function of pathogen; P γ , half maximum pathogen load for f X ; q X , reinvigoration rate due to nivolumab; N 50 , half maximum nivolumab concentration for f r . For further details on the parameters and their estimation, see Table 1 . Meropenem In this work, we modeled the carbapenem antimicrobial agent, meropenem, as the representative antibiotics (7) . For simulating realistic administration regimens of this drug, we chose to model a continuous i.v. administration of meropenem. This is because many physicians today prefer continuous application, to limit the risk of emergence of resistant pathogens under intermittent infusion of this short half-life drug (51) . This is the case even though the superiority of either continuous i.v. administration 1 In the results section the effect of exhausted cells on CTL proliferation is presented as the parameter, s * X = 50 • 10 3 cells/µl − s X , to have the parameter correlate positively with the suppression, for the sake of clarity. or intravenous bolus administration of meropenem for patients with sepsis is still debated (6, 52) . For modeling continuous i.v. administration of meropenem, the drug concentration was described as A(t) = C 0 , with C 0 being the constant meropenem concentration introduced by the injection. Here A(t) is the serum meropenem concentration at time t. The value of C 0 was taken from (6, 8) and was set to 70 mg/L. The PD effects on the pathogen were formulated as a Hill function, as proposed by Regoes et al. (47) : In Equation 9, r P (A) is the pathogen's growth rate as a function of A (see Eq. 4 above); r max is the maximum pathogen growth rate; δ max is the maximum pathogen elimination rate by antibiotics; MIC is the minimum inhibitory concentration (MIC); κ is the steepness of the Hill function (see Table 1 for further details). Since the MIC depends on the specific bacteria (8), we chose to model those bacteria, which have a large enough value of MIC to persist through antibiotic monotherapy, as otherwise there is no a priori purpose to examine the antibiotics and ICB combination. In recent decades, a growing number of bacterial strains have developed significant resistance capabilities to various antimicrobial therapies (53) . This is another motivation for our choice of MIC value. We modeled nivolumab (opdivo R ), a programmed cell death-1 (PD-1) pathway inhibitor hitherto used in oncology, as the representative ICB, exerting its effect on the reinvigoration rate of exhausted CTLs (Figure 1 ). Hotchkiss et al. (19) performed a Phase Ib trial, testing the toxicity of nivolumab in patients with sepsis. The results of this trial did not reveal any unexpected safety findings, nor did it report any drug-related severe adverse events, or evidence for "cytokine storm" in patients. Moreover, in another study by Watanabe et al., the toxicity in exposure to a single dose of nivolumab, 960 mg, was comparable with that of nivolumab, 3 mg/kg every 2 weeks, in the oncological setting (54) . Since Hotchkiss et al.'s trial had a larger sample size, we chose to model the PK/PD dynamics according to their study. The nivolumab serum concentrations therein displayed a predictable PK profile and dose-related increases in exposure. This profile is typical of a two-compartment PK modelblood and well-perfused organs being the central compartment and poorly perfused organs and tissues being the peripheral compartment. Accordingly, a good approximation of the serum drug concentration is where, N 1 + N 2 amounts to the maximal concentration of the drug; N 1 is the initial concentration; N 2 is the equilibrium concentration; λ 1 is the initial nivolumab clearance; λ 2 is the equilibrium nivolumab clearance. We estimated N 1 , N 2 , λ 1 , λ 2 according to the PK parameters in Hotchkiss' study (19) , and by fitting the concentrations, simulated using equation (10) to the observed ones (goodness of fit being, R 2 = 0.87). The parameter estimations appear in Table 1 and explained below. In our model, the PD effect of the ICB drug is expressed as a hyperbolic function: f r (N) =q X N N+N 50 (see Eqs 2, 3, 8) . The parameter N 50 from Eq. 8 is estimated according to Hotchkiss' findings on receptor occupancy, which show a sustained effect of nivolumab for the entire observed period of ∼3 months, even when the drug concentration was significantly reduced. We therefore set this parameter at the relatively low level of 0.3 mg/kg, so that the drug's dose response function reaches saturation relatively quickly. Table 1 contains the meanings and values for the model's parameters. For those parameters with a definite value found in the scientific literature, we assigned that value. Parameters which are noted as "adjusted" were estimated by calculation of their necessary values for the model variables' steady states and simulated ranges to be clinically plausible (those variables being neutrophils, CTLs, pathogen). In order to evaluate the overall benefit of different treatment schedules, we formulated an optimization problem, which would reflect the various goals of the treatment, according to criteria set by the physician. In general, these criteria may be, for example, time to reach a specified disease state, adverse effects, quality of life, cost of treatment, etc. Setting the optimization problem, we formalized the associated fitness function, namely, the objective function that would be used to summarize, as a single figure of merit, how good a given design solution is in achieving the treatment goals according to the set criteria. Subsequently, all the potential design solutions-in our case, the potential treatment schedules and potential personal parameters-were tested by local search heuristics to find a solution, e.g., a specific treatment regimen for a specific patient, which would locally optimize the fitness function (34) . We visualized the results in fitness landscapes, presented as color-schemed heat maps. In this work, we addressed the problem of finding the combined schedule of meropenem and nivolumab, which would best (i) delimit the overall pathogen load and (ii) eliminate the pathogen as early as possible, while (iii) maintaining a sufficiently high level of functioning CTLs, to minimize immunosuppression and maintain the adaptive immune system ready for further pathogen invasions. We set the associated criteria to be • Total pathogen load over time, P(t)dt. • Time until the pathogen is eliminated, T cure . • CTL suppression level, Z L = I L